SCHEMBL20139694

SCHEMBL20139694

Cc1ccc(Br)cc1Cc1ccc2c(c1)C(=O)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL4I1 Q96RQ9 1/20 0.36
METAP1 P53582 1/20 0.35
TDP2 O95551 2/20 0.34
RXRA P19793 3/20 0.33
CMA1 P23946 1/20 0.33
AHR P35869 1/20 0.33
SLC5A1 P13866 1/20 0.32
SLC5A2 P31639 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
PARP1 P09874 2/20 0.32
PDE3B Q13370 2/20 0.32
PDE3A Q14432 2/20 0.32
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
PTGER1 P34995 2/20 0.32
CYP1A2 P05177 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PARP10 Q53GL7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20139413 0.92 METAP1 (0.38) METAP1TDP2RXRACMA1AHR
SCHEMBL20139674 0.86 IL4I1 (0.36) IL4I1METAP1TDP2CMA1AHR
SCHEMBL20140006 0.83 IL4I1 (0.36) IL4I1METAP1TDP2CMA1AHR
SCHEMBL20140009 0.83 KDM4E (0.45) TP53MAPTTDP1L3MBTL1
SCHEMBL20139385 0.78 SLC5A1 (0.48) SLC5A1SLC5A2
SCHEMBL20140286 0.78 METAP1 (0.38) METAP1TDP2CMA1AHRSLC5A1
SCHEMBL20140005 0.75 METAP1 (0.38) METAP1TDP2CMA1AHRSLC5A1
SCHEMBL20139995 0.75 KDM4E (0.45) TP53MAPTTDP1L3MBTL1
SCHEMBL2370367 0.75 METAP1 (0.50) METAP1TDP2CMA1AHRPARP1
SCHEMBL20142219 0.74 FFAR4 (0.40) RXRAFFAR4PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 IL4I1 3911/4885METAP1 2835/4885TDP2 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.